Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

Daniel V.T. Catenacci,Drew W. Rasco,Jeeyun Lee,Sun Young Rha,Keun-Wook Lee,Yung-Jue Bang,Johanna C. Bendell,Peter C. Enzinger,Neyssa Marina,Hong Xiang,Wei Deng,Janine Powers,Zev A. Wainberg

Phase I Escalation and Expansion Study of Bemarituzumab (FPA144) in Patients With Advanced Solid Tumors and FGFR2b-Selected Gastroesophageal Adenocarcinoma

2020

Daniel V.T. Catenacci
Drew W. Rasco
Jeeyun Lee
Sun Young Rha
Keun-Wook Lee
Yung-Jue Bang
Johanna C. Bendell
Peter C. Enzinger
Neyssa Marina
Hong Xiang
Wei Deng
Janine Powers
Zev A. Wainberg

PURPOSETo evaluate the safety, pharmacokinetics, and preliminary activity of bemarituzumab in patients with FGFR2b-overexpressing gastric and gastroesophageal junction adenocarcinoma (GEA).PATIENTS...

Keywords:

Pathology
Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma
Gastroenterology
Internal medicine
Medicine
Pharmacokinetics
gastroesophageal adenocarcinoma
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations